Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

The JOURNAL OF VETERINARY INTERNAL MEDICINE, published by Wiley, serves as an essential platform for disseminating innovative research in veterinary science, specifically focusing on internal medicine. Established in 1987, this esteemed journal has evolved to maintain a strong impact within its field, currently boasting an impressive impact factor and ranking within the top quartile of both general medicine and veterinary categories as of 2023. With an open access policy implemented since 2015, the journal ensures that its critical findings are widely accessible to researchers, practitioners, and students alike, promoting the advancement of knowledge in veterinary care and enhancing the quality of animal health globally. Its Scopus ranking positions it at 23 out of 194 in the general veterinary category, reflecting its high relevance and contribution to ongoing scholarly discourse. By covering contemporary challenges and breakthroughs, the journal provides a crucial resource for those committed to improving veterinary internal medicine.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

JOURNAL OF COMPARATIVE PATHOLOGY, published by Elsevier Science Ltd, stands as a significant publication within the fields of pathology and forensic medicine, as well as veterinary studies. With an ISSN of 0021-9975 and an E-ISSN of 1532-3129, this journal has been disseminating critical research since 1950, contributing to the advancement of knowledge through its focus on comparative pathology. The journal's reputable standing is underscored by its Q3 classification in Pathology and Forensic Medicine and Q2 in Veterinary (miscellaneous) for 2023, reflecting its vital role in shaping contemporary discourse in these domains. The Scopus ranks further solidify its presence, placing it at the 51st percentile in general veterinary sciences and the 32nd percentile in pathology—a testament to the quality and relevance of the contributions it publishes. Although it operates under a subscription model, the journal remains accessible to researchers and practitioners who aim to deepen their understanding of pathological phenomena across species, enhance diagnostic accuracy, and improve clinical practices. With a steadfast commitment to rigorous peer review and a global readership, the JOURNAL OF COMPARATIVE PATHOLOGY is an essential resource for those engaged in research and professional practice, fostering collaborations and innovations that bridge complementary areas of study.

The Journal of Mammary Gland Biology and Neoplasia is an esteemed academic journal published by Springer/Plenum Publishers, focusing on cutting-edge research in the fields of cancer biology and oncology. With an ISSN of 1083-3021 and an E-ISSN of 1573-7039, this journal serves as a vital resource for researchers and practitioners aiming to deepen their understanding of mammary gland biology and its implications in neoplasia. The journal boasts a commendable impact factor, being categorized in the Q2 quartile for both Cancer Research and Oncology as of 2023, indicating its significant influence in these critical areas of study. Additionally, its ranking within Scopus reveals its competitiveness, with a rank of 154 out of 404 in Medicine - Oncology and 128 out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research. Although the journal does not operate under an open access model, it continues to deliver vital insights and findings from 1996 to the present and is committed to advancing knowledge and fostering discussion around mammary gland health and cancer. Researchers, healthcare professionals, and students will find invaluable contributions within its pages, making it a cornerstone publication in the pursuit of cancer research and treatment.

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.